Iproteos

About:

based on the technology transfer from IRB Barcelona and the University of Barcelona.

Website: http://www.iproteos.com/

Twitter/X: iproteos

Top Investors: Criteria Venture Tech, ASCIL Biopharm, Kinled Holding

Description:

Iproteos is a biotech company that focuses its activity on the R&D of new therapeutic strategies based on modulation of protein-ligand (PLI) and protein-protein interactions (PPIs) through peptidomimetics. The novel entities are obtained thanks to the IPRO technology, an innovative platform. Specifically, at Iproteos we apply the IPRO technology on the search for therapeutic agents for the treatment of diseases of the central nervous system (CNS). Based on our expertise in the field, Iproteos is your perfect partner in the discovery of potent and active peptidomimetics for your own targets.

Total Funding Amount:

1.5M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Barcelona, Catalonia, Spain

Founded Date:

2011-06-01

Contact Email:

info(AT)iproteos.com

Founders:

Teresa Tarrago

Number of Employees:

1-10

Last Funding Date:

2016-10-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai